Dr. Shune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6030Fax+1 913-588-4085
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2010 - 2013- University of MinnesotaResidency, Internal Medicine, 2007 - 2010
Istanbul University FomClass of 2004
Certifications & Licensure
KS State Medical License 2014 - 2025
MO State Medical License 2021 - 2025
Clinical Trials
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients Start of enrollment: 2021 Nov 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel
Blood Cancer Journal. 2024-12-05 - BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.Aliya Rashid, William Wesson, Al-Ola Abdallah, Jordan Snyder, Priyanka Venkatesh
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-11 - 1 citationsSafety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet Hakan Kocoglu
Blood. 2024-10-04
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
